Pearse WB, Petrich AM, Gordon LI, Karmali R, et al. A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. Leuk Lymphoma 2021;62:3493-3500.
PMID: 34338127